Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)

被引：4
作者：
Cheema, P. [1 ]
Passaro, A. [2 ]
Martin, C. [3 ]
Tiseo, M. [4 ]
Park, K. [5 ]
Chang, G. [6 ,7 ,8 ]
Hu, Y. [9 ]
Cho, B. C. [10 ]
Miranda, M. [11 ]
Fernandes, A. [12 ]
Freitas, H. [13 ]
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, William Osler Hlth Syst, Toronto, ON, Canada
[2] European Inst Oncol Irccs, Ieo, Div Thorac Oncol, Milan, Italy
[3] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[6] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Fac Med, Sch Med, Taichung, Taiwan
[8] Natl Yang Ming Univ, Taichung, Taiwan
[9] Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[12] Astrazeneca Us, Gaithersburg, MD USA
[13] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; EGFR; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-59
引用
收藏
页码：S854 / S854
页数：1
相关论文
共 50 条
  • [21] Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
    Santos, Edgardo
    Kaplan, Barry
    Kirshner, Eli
    Croft, Elisabeth
    Sequist, Lecia
    Burke, Lea
    Munley, Jiefen
    Oxnard, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1237
  • [22] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [23] A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
    Jiang, R.
    Wang, X.
    Wang, L.
    Huang, D.
    Ding, C.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S346 - S347
  • [24] EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
    Hochmair, Maximilian
    Holzer, Sophia
    Filipits, Martin
    Mohn-Staudner, Andrea
    Errhalt, Peter
    Absenger, Gudrun
    Bundalo, Tatjana
    Arns, Madeleine
    Setinek, Ulrike
    Mikes, Romana
    Kolb, Rainer
    Schumacher, Michael
    Zoechbauer-Mueller, Sabine
    Patocka, Kurt
    Haslbauer, Ferdinand
    Rudzki, Jakob
    Burghuber, Otto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1254
  • [25] Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
    Tung, Pi-Hung
    Chiu, Tzu-Hsuan
    Huang, Allen Chung-Cheng
    Ju, Jia-Shiuan
    Huang, Chi-Hsien
    Wang, Chin-Chou
    Ko, How-Wen
    Chung, Fu-Tsai
    Hsu, Ping-Chih
    Fang, Yueh-Fu
    Guo, Yi-Ke
    Kuo, Chih-Hsi Scott
    Yang, Cheng-Ta
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [26] Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
    Hochmair, M.
    Schwab, S.
    Burghuber, O.
    Koger, R.
    Setinek, U.
    Cseh, A.
    Fritz, R.
    Buder, A.
    Filipits, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2136 - S2136
  • [27] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [28] Real-World Safety and Efficacy Data of Osimertinib in Patients from Japan with EGFR T790M-Positive NSCLC
    Ohe, Y.
    Kato, T.
    Shimizu, W.
    Sakamoto, K.
    Sugeno, M.
    Tamura, R.
    Tokimoto, T.
    Gemma, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S852 - S852
  • [29] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
    Zhang, Yidan
    Xu, Yingqi
    Xu, Jianlin
    Zhong, Hua
    Xia, Jinjing
    Zhong, Runbo
    CANCER SCIENCE, 2024, : 753 - 763
  • [30] Clinical Outcomes of Patients with EGFR T790M+NSCLC on Osimertinib
    Tan, W. L.
    Hennedige, T. P.
    Ng, Q. S.
    Tan, S. H.
    Tran, N. T. A.
    Chua, B. J. G.
    Toh, C. K.
    Tan, E. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Lim, T. K. H.
    Gogna, A.
    Koh, M.
    Yip, C. S. P.
    Thng, C. H.
    Chowbay, B.
    Tan, M. H.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2206 - S2206
12345